PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25124560-10	2014	Furthermore, we discuss nanotechnological advances with emphasis on PEG-TRAIL and four-arm PEG cross-linked hyaluronic acid (HA) hydrogels to improve availability of TRAIL at target sites.	Hyaluronic Acid	108-123	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	166-171	
25124560-10	2014	Furthermore, we discuss nanotechnological advances with emphasis on PEG-TRAIL and four-arm PEG cross-linked hyaluronic acid (HA) hydrogels to improve availability of TRAIL at target sites.	Hyaluronic Acid	125-127	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	166-171	
21098223-7	2011	LMM hyaluronan-induced inflammatory neutrophil apoptosis was substantially prevented by anti-TRAIL neutralizing mAb.	Hyaluronic Acid	4-14	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	93-98	
21098223-8	2011	We conclude that decreased IFN-beta levels decrease the activity of the TRAIL/TRAILR system in TLR4-deficient neutrophils, leading to impaired apoptosis of neutrophils and resulting in abnormal accumulation of neutrophils in the lungs of LMM hyaluronan-treated mice.	Hyaluronic Acid	242-252	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	72-77	
20813405-8	2010	These results imply that HA/PEG-TRAIL nanocomplex formulations are promising therapeutic modalities for the treatment of RA.	Hyaluronic Acid	25-27	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	28-37